New LightCycler PCR for Rapid and Sensitive Quantification of Parvovirus B19 DNA Guides Therapeutic Decision-Making in Relapsing Infections

ABSTRACT Detection of parvovirus B19 DNA offers diagnostic advantages over serology, particularly in persistent infections of immunocompromised patients. A rapid, novel method of B19 DNA detection and quantification is introduced. This method, a quantitative PCR assay, is based on real-time glass capillary thermocycling (LightCycler [LC]) and fluorescence resonance energy transfer (FRET). The PCR assay allowed quantification over a dynamic range of over 7 logs and could quantify as little as 250 B19 genome equivalents (geq) per ml as calculated for plasmid DNA (i.e., theoretically ≥5 geq per assay). Interrater agreement analysis demonstrated equivalence of LC-FRET PCR and conventional nested PCR in the diagnosis of an active B19 infection (kappa coefficient = 0.83). The benefit of the new method was demonstrated in an immunocompromised child with a relapsing infection, who required an attenuation of the immunosuppressive therapy in addition to repeated doses of immunoglobulin to eliminate the virus.

[1]  J. Murray,et al.  B19 parvovirus-induced anemia in a normal child. Initial bone marrow erythroid hyperplasia and response to intravenous immunoglobulin. , 1993, The American journal of pediatric hematology/oncology.

[2]  T. Moore Parvovirus-associated arthritis , 2000, Current opinion in rheumatology.

[3]  G. Massey,et al.  Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients. , 1990, The Journal of pediatrics.

[4]  K. Druschky,et al.  Chronic parvovirus B-19 meningoencephalitis with additional detection of Epstein-Barr virus DNA in the cerebrospinal fluid of an immunocompetent patient. , 2000, Journal of neurovirology.

[5]  H. Lankinen,et al.  Acute-Phase-Specific Heptapeptide Epitope for Diagnosis of Parvovirus B19 Infection , 1999, Journal of Clinical Microbiology.

[6]  J. Henter,et al.  Persistent B19 parvovirus infection in pediatric malignancies. , 1998, Medical and pediatric oncology.

[7]  J. Fleiss Statistical methods for rates and proportions , 1974 .

[8]  K. Hedman,et al.  Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. , 1995, The Journal of infectious diseases.

[9]  C. Teter,et al.  Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: Use of intravenous immunoglobulin—A report of eight patients , 1999, American journal of hematology.

[10]  S. Girotti,et al.  Development of a chemiluminescence competitive PCR for the detection and quantification of parvovirus B19 DNA using a microplate luminometer. , 1999, Clinical chemistry.

[11]  S. Zolla-Pazner,et al.  Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. , 1993, The Journal of infectious diseases.

[12]  E Schütz,et al.  Spreadsheet software for thermodynamic melting point prediction of oligonucleotide hybridization with and without mismatches. , 1999, BioTechniques.

[13]  D. W. Jenkins,et al.  Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. , 1989, The New England journal of medicine.

[14]  G. Siegl,et al.  Quantitative Evidence for Persistence of Human Parvovirus B19 DNA in an Immunocompetent Individual , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  K. Sugamura,et al.  Human parvovirus B19 as a causative agent for rheumatoid arthritis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Modrow,et al.  Lymphoproliferative responses after infection with human parvovirus B19 , 1996, Journal of virology.

[17]  M. Pallansch,et al.  Multiple primer pairs for polymerase chain reaction (PCR) amplification of human parvovirus B19 DNA. , 1993, Journal of virological methods.

[18]  A. Hornsleth,et al.  Parvovirus: the expanding spectrum of disease , 1995, Acta paediatrica.

[19]  J. Abkowitz,et al.  Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. , 1997, Journal of Infectious Diseases.

[20]  K. Hedman,et al.  T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19. , 2001, The Journal of infectious diseases.

[21]  N. Young Parvovirus infection and its treatment , 1996, Clinical and experimental immunology.

[22]  M. Vidaud,et al.  Large–Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for Fractionation , 2000, Vox Sanguinis.

[23]  U J Balis,et al.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.

[24]  N. Young,et al.  Chronic bone marrow failure due to persistent B19 parvovirus infection. , 1987, The New England journal of medicine.

[25]  K. Hedman,et al.  Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. , 1999, Scandinavian journal of infectious diseases.

[26]  Brown Ke,et al.  Parvovirus B19 in human disease. , 1997 .

[27]  F. Falkner,et al.  Quantitation of Viral DNA by Real-Time PCR Applying Duplex Amplification, Internal Standardization, and Two-Color Fluorescence Detection , 2001, Applied and Environmental Microbiology.

[28]  N. Young,et al.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection. , 1989, The Journal of clinical investigation.

[29]  S. Modrow,et al.  Persistent parvovirus B19 infections in immunocompromised children , 1998, Medical Microbiology and Immunology.

[30]  P. Boulanger,et al.  Rapid and sensitive method for the detection of B19 virus DNA using the polymerase chain reaction with nested primers. , 1993, Journal of virological methods.

[31]  K. Broliden,et al.  Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. , 1999, Scandinavian journal of infectious diseases.

[32]  S. Kajigaya,et al.  A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response , 1991, Journal of virology.

[33]  E. Heegaard,et al.  Estimation of serum concentration of parvovirus B19 DNA by PCR in patients with chronic anaemia. , 1994, Research in virology.

[34]  M Gessner,et al.  A quantitative, internally controlled real-time PCR Assay for the detection of parvovirus B19 DNA. , 2001, Journal of virological methods.

[35]  K. Kamisango,et al.  Development of a Hypersensitive Detection Method for Human Parvovirus B19 DNA , 2000, Journal of Clinical Microbiology.

[36]  L. Anderson,et al.  Chronic parvovirus infection in a presumably immunologically healthy woman. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  D. Erdman,et al.  Detection of human parvovirus B19 DNA PCR products by RNA probe hybridization enzyme immunoassay , 1994, Journal of clinical microbiology.

[38]  R. Schild,et al.  Prenatal diagnosis of congenital parvovirus B19 infection: value of serological and PCR techniques in maternal and fetal serum , 1999, Prenatal diagnosis.

[39]  P. Klenerman,et al.  Direct Ex Vivo Measurement of CD8+T-Lymphocyte Responses to Human Parvovirus B19 , 2001, Journal of Virology.

[40]  Quang Tri Nguyen,et al.  Novel Human Erythrovirus Associated with Transient Aplastic Anemia , 1999, Journal of Clinical Microbiology.

[41]  R. Schild,et al.  Parvovirus B19 Infection in Pregnancy , 1999, Intervirology.

[42]  H. Sato,et al.  Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies , 1991, Journal of virology.

[43]  K. Brown,et al.  Haematological consequences of parvovirus B19 infection. , 2000, Bailliere's best practice & research. Clinical haematology.

[44]  S. Zolla-Pazner,et al.  Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins , 1999, Journal of Virology.

[45]  J. Moore,et al.  Parvovirus B19 infection--persistence and genetic variation. , 1995, Scandinavian journal of infectious diseases.

[46]  S. Doyle,et al.  Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG , 1999, Journal of medical virology.

[47]  N. Young,et al.  Erythrocyte P antigen: cellular receptor for B19 parvovirus. , 1993, Science.

[48]  N. Young,et al.  Parvovirus B19 in human disease. , 1997, Annual review of medicine.

[49]  S. Modrow,et al.  Seroprevalence of parvovirus B19 NS1‐specific IgG in B19‐infected and uninfected individuals and in infected pregnant women , 2000, Journal of medical virology.